Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development Updates
Initiated EQUATOR Phase 3 study of itolizumab in first-line aGVHD
Acquired Bioniz Therapeutics, adding two first-in-class clinical-stage assets to pipeline and proprietary product discovery platform
Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the first quarter 2022 and provided an update on its corporate development and clinical programs.
"It's been a transformative start to the year, leading to significant enhancements in how we are building value going forward," said Bruce Steel, chief executive office
